XTALPI (02228) has released its annual results for the period ending December 31, 2025. The group recorded revenue of RMB 8.03 billion, an increase of 201.25% year-on-year. Profit attributable to equity holders for the year amounted to RMB 124 million, marking a turnaround from a loss in the previous year. Earnings per share were RMB 0.03.

This represents the group's first annual profit, making it the first publicly listed company in Hong Kong specializing in AI for Science to achieve profitability. During the period, the group achieved several key milestones: 1) It empowered and incubated more than five first-in-class or best-in-class innovative pipelines into clinical or IND-enabling stages, spanning areas such as oncology, autoimmune diseases, neurodegenerative disorders, and chronic illnesses. 2) Multiple high-value collaborations were secured, with cumulative contract values reaching tens of billions of RMB, solidifying its leading position in applied AI. 3) The number of revenue-generating customers grew by 62% year-on-year in 2025. To date, the group has engaged 17 of the world’s top 20 pharmaceutical companies, successfully delivering across multiple scenarios and earning recognition from leading international clients. 4) The group has developed over 200 industry-specific AI models and expanded into new drug innovation platforms in 2025, including molecular glues, peptides, and small nucleic acids, further strengthening its full-stack capabilities. 5) Its AI agents independently conduct tens of thousands of compound experiments weekly, achieving a closed-loop R&D process. 6) The group has successfully entered new fields such as new materials and consumer health.

These milestones signify that the group’s "AI + robotics" platform has entered a phase of scaled value realization, laying a solid foundation for sustainable, high-quality growth. As of December 31, 2025, the group’s cash balance totaled RMB 7.069 billion. In 2026, it issued convertible bonds with net proceeds of RMB 2.537 billion, providing strong financial backing for continued R&D investment and further cementing XTALPI’s leadership in the AI for Science sector.

During the reporting period, the group was also successfully included in the MSCI China Small Cap Index, MSCI China Index, and the Hang Seng Tech Index, receiving dual authoritative recognition from international capital markets for its investment value and core industry standing.